NEW YORK CITY, NY / ACCESS Newswire / March 16, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds ...

GSK said this month that it’s making progress in late-stage development of several oncology drugs, though vaccine sales are falling.

GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...

Two recent high-profile acquisitions exemplify this trend; Eli Lilly’s pursuit of Scorpion Therapeutics and GSK’s acquisition of IDRx. Eli Lilly’s Bold Bid to Lead Oncology Eli Lilly’s ...

Of 12 evaluable patients, four experienced a partial response, translating to a 33% response rate, while one patient achieved ...

GSK reported core earnings of 59 cents per American ... Sales grew in double digits in HIV, Immunology/Respiratory as well as Oncology segments. HIV sales rose 14% driven by strong demand and ...

Hesham Abdullah, GSK's Senior Vice President, Global Head Oncology R&D, stated, "This acquisition adds to GSK's growing pipeline of targeted therapeutics for cancers originating in the ...